Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03455699 · ClinicalTrials.gov registry record

VeClose Five Year Follow-Up Extension Study

A clinical trial of Great Saphenous Vein (GSV) With Venous Reflux Disease, sponsored by Medtronic Endovascular.

Completed
Registry status
114
Enrollment target
9
Study locations

NCT03455699: Completed study of Great Saphenous Vein (GSV) With Venous Reflux Disease, sponsored by Medtronic Endovascular.

NCT03455699 is a study of Great Saphenous Vein (GSV) With Venous Reflux Disease that has completed, run by Medtronic Endovascular. The registered enrollment target is 114 participants. The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03455699, a study of Great Saphenous Vein (GSV) With Venous Reflux Disease, has completed, sponsored by Medtronic Endovascular.

COMPLETED
Registry status
114 participants
Enrollment target
9
Study locations

Study Summary

The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).

Interventions

  • DEVICE VenaSeal SCS
  • DEVICE ClosureFast Radiofrequency Ablation (RFA)
  • DEVICE Roll-In (VenaSeal SCS)

Study Locations (9)

Arizona

  • Morrison Vein Institute - Scottsdale

California

  • GBK Cosmetic Laser Dermatology - San Diego

Colorado

  • Radiology Imaging Associates (RIA) - Greenwood Village

Illinois

  • Prairie Education & Research Cooperative - Springfield

Maryland

  • MD Laser Skin & Vein Institute - Hunt Valley

New York

  • Vein Institute of Buffalo - North Tonawanda

Oregon

  • Inovia Vein Speciality Center - Bend

Virginia

  • Sentara Vascular Specialists - Virginia Beach

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2016-07
Est. Completion 2019-01

Sponsor

Medtronic Endovascular

25 total trials

What the Registry Record Tells You About NCT03455699

The ClinicalTrials.gov registry entry for NCT03455699 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Endovascular, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Great Saphenous Vein (GSV) With Venous Reflux Disease appearing as the primary indexed condition, and to 3 interventions - of which VenaSeal SCS is the first listed.

NCT03455699 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT03455699 about?

NCT03455699 is a clinical study titled "VeClose Five Year Follow-Up Extension Study". The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).

What is the current status of trial NCT03455699?

This trial is currently completed. The enrollment target is 114 participants. The study started on 2016-07. Estimated completion is 2019-01.

What conditions does trial NCT03455699 study?

This clinical trial studies the following conditions: Great Saphenous Vein (GSV) With Venous Reflux Disease.

What interventions are being tested in trial NCT03455699?

The interventions under investigation include: VenaSeal SCS (DEVICE), ClosureFast Radiofrequency Ablation (RFA) (DEVICE), Roll-In (VenaSeal SCS) (DEVICE).

Who is sponsoring clinical trial NCT03455699?

This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03455699 being conducted?

This trial has 9 study locations across Arizona, California, Colorado, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Great Saphenous Vein (GSV) With Venous Reflux Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.